Engineered FGF19[DELA]KLB protects against intrahepatic cholestatic liver injury in ANIT-induced and...
Engineered FGF19[DELA]KLB protects against intrahepatic cholestatic liver injury in ANIT-induced and Mdr2-/- mice model
About this item
Full title
Author / Creator
Shi, Lu , Zhao, Tiantian , Huang, Lei , Pan, Xiaomin , Wu, Tianzhen , Feng, Xin , Chen, Taoli , Wu, Jiamin and Niu, Jianlou
Publisher
BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
The major safety concern of the clinical application of wild type FGF19 (FGF19.sup.WT) emerges given that its extended treatment causes hepatocellular carcinoma. Therefore, we previously generated a safer FGF19 variant - FGF19.sup.[DELA]KLB, which have same effects on glycemic control and bile acid production but much less mitogenic activity. Howev...
Alternative Titles
Full title
Engineered FGF19[DELA]KLB protects against intrahepatic cholestatic liver injury in ANIT-induced and Mdr2-/- mice model
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A767689994
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A767689994
Other Identifiers
ISSN
1472-6750
E-ISSN
1472-6750
DOI
10.1186/s12896-023-00810-9
